| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16816 R70550 |
Christensen (Phenobarbital) (Epilepsy) (Controls exposed to LTG), 2024 | Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.52 [0.68;3.42] C excluded (control group) |
7/47 546/5,299 | 553 | 47 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16817 R70551 |
Christensen (Phenobarbital) (Epilepsy) (Controls unexposed, general population), 2024 | Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.51 [0.67;3.43] | 7/47 2,416/22,227 | 2,423 | 47 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8704 R29342 |
Coste (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2020 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
2.26 [1.31;3.90] C excluded (control group) |
17/84 284/2,813 | 301 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8705 R29360 |
Coste (Phenobarbital) (Controls unexposed, NOS), 2020 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.34 [1.37;3.98] C | 17/84 167,376/1,710,441 | 167,393 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8703 R29334 |
Hernández-Díaz (Phenobarbital), 2017 | Small for gestational age (<10th percentile) | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 2.40 [1.60;3.60] | -/178 -/1,799 | - | 178 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8648 R29032 |
Burja (Phenobarbital or Primidone) (Controls unexposed, disease free), 2006 | Small for date (NOS) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No |
8.17 [0.49;135.15] C excluded (control group) |
1/2 23/211 | 24 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8649 R29037 |
Burja (Phenobarbital or Primidone) (Controls unexposed, sick), 2006 | Small for date (NOS) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 31.00 [1.02;941.06] C | 1/2 1/32 | 2 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8653 R29117 |
Endo (Phenobarbital) (Controls unexposed, disease free), 2004 | Intrauterine growth retardation (NOS) | throughout pregnancy | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
0.95 [0.05;16.63] C excluded (control group) |
0/10 34/656 | 34 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8654 R29132 |
Endo (Phenobarbital) (Controls unexposed, sick), 2004 | Intrauterine growth retardation (NOS) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.05 [0.00;6.68] C | 0/10 0/1 | 0 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 2.19 [1.44;3.35] | 169,818 | 321 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Phenobarbital) (Epilepsy) (Controls unexposed, general population; 2: Phenobarbital) (Controls unexposed, NOS; 3: Phenobarbital; 4: Phenobarbital or Primidone) (Controls unexposed, sick; 5: Phenobarbital) (Controls unexposed, sick;
Asymetry test p-value = 0.7913 (by Egger's regression)
slope=0.8925 (0.3498); intercept=-0.2972 (1.0279); t=0.2892; p=0.7913
excluded 8653, 8648, 8704, 16816